{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T13:40:30Z","timestamp":1785246030607,"version":"3.55.0"},"reference-count":49,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T00:00:00Z","timestamp":1666224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>In October 2020, the FDA granted regular approval to venetoclax (ABT-199) in combination with hypomethylating agents for newly-diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or in patients with comorbidities precluding intensive chemotherapy. The treatment response to venetoclax combination treatment, however, may be short-lived, and leukemia relapse is the major cause of treatment failure. Multiple studies have confirmed the upregulation of the anti-apoptotic proteins of the B-cell lymphoma 2 (BCL2) family and the activation of intracellular signaling pathways associated with resistance to venetoclax. To improve treatment outcome, compounds targeting anti-apoptotic proteins and signaling pathways have been evaluated in combination with venetoclax. In this study, the BCL-XL inhibitor A1331852, MCL1-inhibitor S63845, dual PI3K-mTOR inhibitor bimiralisib (PQR309), BMI-1 inhibitor unesbulin (PTC596), MEK-inhibitor trametinib (GSK1120212), and STAT3 inhibitor C-188-9 were assessed as single agents and in combination with venetoclax, for their ability to induce apoptosis and cell death in leukemic cells grown in the absence or presence of bone marrow stroma. Enhanced cytotoxic effects were present in all combination treatments with venetoclax in AML cell lines and AML patient samples. Elevated in vitro efficacies were observed for the combination treatment of venetoclax with A1331852, S63845 and bimiralisib, with differing response markers for each combination. For the venetoclax and bimiralisib combination treatment, responders were enriched for IDH2 and FLT3 mutations, whereas non-responders were associated with PTPN11 mutations. The combination of PI3K\/mTOR dual pathway inhibition with bimiralisib and BCL2 inhibition with venetoclax has emerged as a candidate treatment in IDH2- and FLT3-mutated AML.<\/jats:p>","DOI":"10.3390\/ijms232012587","type":"journal-article","created":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T22:49:46Z","timestamp":1666306186000},"page":"12587","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Rationale for Combining the BCL2 Inhibitor Venetoclax with the PI3K Inhibitor Bimiralisib in the Treatment of IDH2- and FLT3-Mutated Acute Myeloid Leukemia"],"prefix":"10.3390","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3128-1573","authenticated-orcid":false,"given":"Katja","family":"Seipel","sequence":"first","affiliation":[{"name":"Department for Biomedical Research (DBMR), University of Bern, 2008 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvo","family":"Br\u00fcgger","sequence":"additional","affiliation":[{"name":"Department for Biomedical Research (DBMR), University of Bern, 2008 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8753-7078","authenticated-orcid":false,"given":"Harpreet","family":"Mandhair","sequence":"additional","affiliation":[{"name":"Department for Biomedical Research (DBMR), University of Bern, 2008 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8771-947X","authenticated-orcid":false,"given":"Ulrike","family":"Bacher","sequence":"additional","affiliation":[{"name":"Department of Hematology, University Hospital Bern, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6055-5257","authenticated-orcid":false,"given":"Thomas","family":"Pabst","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University Hospital Bern, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Fleischmann, M., Schnetzke, U., Hochhaus, A., and Scholl, S. (2021). Management of Acute Myeloid Leukemia: Current Treatment Options and Future Perspectives. Cancers, 13.","DOI":"10.3390\/cancers13225722"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11864-020-00765-5","article-title":"Treatment of Relapsed Acute Myeloid Leukemia","volume":"21","author":"Thol","year":"2020","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax Combined with Decitabine or Azacitidine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular Patterns of Response and Treatment Failure after Frontline Venetoclax Combinations in Older Patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/bloodadvances.2020003734","article-title":"Clinical and Molecular Predictors of Response and Survival Following Venetoclax Therapy in Relapsed\/Refractory AML","volume":"5","author":"Stahl","year":"2021","journal-title":"Blood Adv."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Salah, H.T., DiNardo, C.D., Konopleva, M., and Khoury, J.D. (2021). Potential Biomarkers for Treatment Response to the BCL-2 Inhibitor Venetoclax: State of the Art and Future Directions. Cancers, 13.","DOI":"10.3390\/cancers13122974"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e549","DOI":"10.1097\/HS9.0000000000000549","article-title":"Safety and Efficacy: Clinical Experience of Venetoclax in Combination With Hypomethylating Agents in Both Newly Diagnosed and Relapsed\/Refractory Advanced Myeloid Malignancies","volume":"5","author":"Feld","year":"2021","journal-title":"Hemasphere"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"106735","DOI":"10.1016\/j.leukres.2021.106735","article-title":"RUNX1 Mutations Correlate with Response to Venetoclax Combination Therapies in Relapsed\/Refractory Acute Myeloid Leukemia","volume":"111","author":"Chow","year":"2021","journal-title":"Leuk. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"E202","DOI":"10.1002\/ajh.25146","article-title":"Genetic Biomarkers Of Sensitivity and Resistance to Venetoclax Monotherapy in Patients With Relapsed Acute Myeloid Leukemia","volume":"93","author":"Chyla","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1158\/2159-8290.CD-19-0125","article-title":"The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells","volume":"9","author":"Nechiporuk","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/s41419-019-2156-2","article-title":"Side-by-Side Comparison of BH3-Mimetics Identifies MCL-1 as a Key Therapeutic Target in AML","volume":"10","author":"Ewald","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.3324\/haematol.2019.220525","article-title":"Specific Interactions of BCL-2 Family Proteins Mediate Sensitivity to BH3-Mimetics in Diffuse Large B-Cell Lymphoma","volume":"105","author":"Smith","year":"2020","journal-title":"Haematologica"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nature19830","article-title":"The MCL1 Inhibitor S63845 Is Tolerable and Effective in Diverse Cancer Models","volume":"538","author":"Kotschy","year":"2016","journal-title":"Nature"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Seipel, K., Schmitter, K., Bacher, U., and Pabst, T. (2019). Rationale for a Combination Therapy Consisting of MCL1- and MEK-Inhibitors in Acute Myeloid Leukemia. Cancers, 11.","DOI":"10.3390\/cancers11111779"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Seipel, K., Kopp, B., Bacher, U., and Pabst, T. (2021). BMI1-Inhibitor PTC596 in Combination with MCL1 Inhibitor S63845 or MEK Inhibitor Trametinib in the Treatment of Acute Leukemia. Cancers, 13.","DOI":"10.3390\/cancers13030581"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/s41409-022-01679-6","article-title":"Venetoclax-Based Regimens in Combination with Trametinib for RAS-Mutated Relapsed or Refractory Myeloid Malignancies","volume":"57","author":"Kevlicius","year":"2022","journal-title":"Bone Marrow Transpl."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Seipel, K., Graber, C., Fl\u00fcckiger, L., Bacher, U., and Pabst, T. (2021). Rationale for a Combination Therapy with the STAT5 Inhibitor AC-4-130 and the MCL1 Inhibitor S63845 in the Treatment of FLT3-Mutated or TET2-Mutated Acute Myeloid Leukemia. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22158092"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3324\/haematol.2018.205534","article-title":"Concomitant Targeting of BCL2 with Venetoclax and MAPK Signaling with Cobimetinib in Acute Myeloid Leukemia Models","volume":"105","author":"Han","year":"2020","journal-title":"Haematologica"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/s41375-021-01502-z","article-title":"Synergistic Activity of Combined Inhibition of Anti-Apoptotic Molecules in B-Cell Precursor ALL","volume":"36","author":"Seyfried","year":"2022","journal-title":"Leukemia"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Bewarder, M., Stilgenbauer, S., Thurner, L., and Kaddu-Mulindwa, D. (2021). Current Treatment Options in CLL. Cancers, 13.","DOI":"10.3390\/cancers13102468"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1182\/blood.2019002841","article-title":"How I Manage CLL with Venetoclax-Based Treatments","volume":"135","author":"Wierda","year":"2020","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Watanabe, D., Nogami, A., Okada, K., Akiyama, H., Umezawa, Y., and Miura, O. (2019). FLT3-ITD Activates RSK1 to Enhance Proliferation and Survival of AML Cells by Activating MTORC1 and EIF4B Cooperatively with PIM or PI3K and by Inhibiting Bad and BIM. Cancers, 11.","DOI":"10.3390\/cancers11121827"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Nepstad, I., Hatfield, K.J., Gr\u00f8nnings\u00e6ter, I.S., and Reikvam, H. (2020). The PI3K-Akt-MTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21082907"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Darici, S., Alkhaldi, H., Horne, G., J\u00f8rgensen, H.G., Marmiroli, S., and Huang, X. (2020). Targeting PI3K\/Akt\/MTOR in AML: Rationale and Clinical Evidence. J. Clin. Med., 9.","DOI":"10.3390\/jcm9092934"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1158\/0008-5472.CAN-17-3024","article-title":"Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML Cells","volume":"78","author":"Rahmani","year":"2018","journal-title":"Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"7524","DOI":"10.1021\/acs.jmedchem.7b00930","article-title":"5-(4,6-Dimorpholino-1,3,5-Triazin-2-Yl)-4-(Trifluoromethyl)Pyridin-2-Amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K\/MTOR Inhibitor as Clinical Candidate in Oncology","volume":"60","author":"Beaufils","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1158\/1078-0432.CCR-17-1041","article-title":"PQR309 Is a Novel Dual PI3K\/MTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy","volume":"24","author":"Tarantelli","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e656","DOI":"10.1097\/HS9.0000000000000656","article-title":"A Phase II Study to Assess the Safety and Efficacy of the Dual MTORC1\/2 and PI3K Inhibitor Bimiralisib (PQR309) in Relapsed, Refractory Lymphoma","volume":"5","author":"Collins","year":"2021","journal-title":"Hemasphere"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e527","DOI":"10.1038\/bcj.2017.8","article-title":"The Novel BMI-1 Inhibitor PTC596 Downregulates MCL-1 and Induces P53-Independent Mitochondrial Apoptosis in Acute Myeloid Leukemia Progenitor Cells","volume":"7","author":"Nishida","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3727\/096504016X14634208143021","article-title":"Induction of Multidrug Resistance of Acute Myeloid Leukemia Cells by Cocultured Stromal Cells via Upregulation of the PI3K\/Akt Signaling Pathway","volume":"24","author":"Chen","year":"2016","journal-title":"Oncol. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ejca.2018.03.012","article-title":"First-in Human, Phase 1, Dose-Escalation Pharmacokinetic and Pharmacodynamic Study of the Oral Dual PI3K and MTORC1\/2 Inhibitor PQR309 in Patients with Advanced Solid Tumors (SAKK 67\/13)","volume":"96","author":"Wicki","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1021\/acsmedchemlett.9b00568","article-title":"Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-XL Inhibitor","volume":"11","author":"Wang","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/cpdd.904","article-title":"Pharmacokinetics and Safety of PTC596, a Novel Tubulin-Binding Agent, in Subjects With Advanced Solid Tumors","volume":"10","author":"Shapiro","year":"2021","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.cca.2017.07.012","article-title":"Trough Dabrafenib Plasma Concentrations Can Predict Occurrence of Adverse Events Requiring Dose Reduction in Metastatic Melanoma","volume":"472","author":"Rousset","year":"2017","journal-title":"Clin. Chim. Acta"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"26307","DOI":"10.18632\/oncotarget.8368","article-title":"Small-Molecule Inhibition of STAT3 in Radioresistant Head and Neck Squamous Cell Carcinoma","volume":"7","author":"Bharadwaj","year":"2016","journal-title":"Oncotarget"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"5701","DOI":"10.1182\/blood-2010-04-280123","article-title":"Stat3 Signaling in Acute Myeloid Leukemia: Ligand-Dependent and -Independent Activation and Induction of Apoptosis by a Novel Small-Molecule Stat3 Inhibitor","volume":"117","author":"Redell","year":"2011","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1182\/blood.V88.7.2442.bloodjournal8872442","article-title":"Granulocyte Colony-Stimulating Factor Activation of Stat3\u03b1 and Stat3\u03b2 in Immature Normal and Leukemic Human Myeloid Cells","volume":"88","author":"Chakraborty","year":"1996","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.21037\/atm-20-3191","article-title":"Stromal Cells Promote Chemoresistance of Acute Myeloid Leukemia Cells via Activation of the IL-6\/STAT3\/OXPHOS Axis","volume":"8","author":"Hou","year":"2020","journal-title":"Ann. Transl. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"865","DOI":"10.4066\/biomedicalresearch.29-17-2410","article-title":"Bone Marrow Stromal-Cell Line HS-5 Affects Apoptosis of Acute Myeloid Leukemia Cells HL-60 through GLI1 Activation","volume":"29","author":"Guan","year":"2018","journal-title":"Biomed Res"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"584232","DOI":"10.3389\/fcell.2020.584232","article-title":"HS-5 and HS-27A Stromal Cell Lines to Study Bone Marrow Mesenchymal Stromal Cell-Mediated Support to Cancer Development","volume":"8","author":"Adamo","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.3389\/fonc.2019.01135","article-title":"The Yin and Yang of the Bone Marrow Microenvironment: Pros and Cons of Mesenchymal Stromal Cells in Acute Myeloid Leukemia","volume":"9","author":"Ciciarello","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Bolandi, S.M., Pakjoo, M., Beigi, P., Kiani, M., Allahgholipour, A., Goudarzi, N., Khorashad, J.S., and Eiring, A.M. (2021). A Role for the Bone Marrow Microenvironment in Drug Resistance of Acute Myeloid Leukemia. Cells, 10.","DOI":"10.3390\/cells10112833"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/ejh.13492","article-title":"Pairing MCL-1 Inhibition with Venetoclax Improves Therapeutic Efficiency of BH3-Mimetics in AML","volume":"105","author":"Hormi","year":"2020","journal-title":"Eur. J. Haematol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3324\/haematol.2020.260331","article-title":"Targeting MCL-1 Dysregulates Cell Metabolism and Leukemia-Stroma Interactions and Resensitizes Acute Myeloid Leukemia to BCL-2 Inhibition","volume":"107","author":"Carter","year":"2022","journal-title":"Haematologica"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/s43018-020-0103-x","article-title":"Integrated Analysis of Patient Samples Identifies Biomarkers for Venetoclax Efficacy and Combination Strategies in Acute Myeloid Leukemia","volume":"1","author":"Zhang","year":"2020","journal-title":"Nat. Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-021-00541-0","article-title":"ASXL1 Mutations Are Associated with Distinct Epigenomic Alterations That Lead to Sensitivity to Venetoclax and Azacytidine","volume":"11","author":"Rahmani","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.blre.2018.04.008","article-title":"Current Status and Trends in the Diagnostics of AML and MDS","volume":"32","author":"Shumilov","year":"2018","journal-title":"Blood Rev."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/20\/12587\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:57:53Z","timestamp":1760144273000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/20\/12587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,20]]},"references-count":49,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["ijms232012587"],"URL":"https:\/\/doi.org\/10.3390\/ijms232012587","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,20]]}}}